| Project/Area Number |
04670794
|
|---|
| Research Category |
Grant-in-Aid for General Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Nagoya City University |
|---|
Principal Investigator |
YOTSUYANAGI Toshihisa Nagoya City University, Faculty of Pharmaceutical Sciences, Professor., 薬学部, 教授 (40080189)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
MIZUNO Isamu Nagoya City University, Medical School, Lecturer., 医学部, 講師 (20157506)
|
|---|
| Project Period (FY) |
1992 – 1993
|
| Project Status |
Completed (Fiscal Year 1993)
|
| Budget Amount *help |
¥2,000,000 (Direct Cost: ¥2,000,000)
Fiscal Year 1993: ¥700,000 (Direct Cost: ¥700,000)
Fiscal Year 1992: ¥1,300,000 (Direct Cost: ¥1,300,000)
|
|---|
| Keywords | liposome / carboplatin / intraperitoneal administration / intraportal vein administration |
|---|
| Research Abstract |
We examinde the distribution in tissues and antitumor effects of freezedried liposome-entrapped carboplatin(Lipo-CBDCA) after intraperitoneal administration to rats bearing AH130 tumors. The serum concentration of platinum was decreased for a short time after the intraperitoneal administration of lipo-CBDCA.After at least 3 hours, the serum concentration of platinum was higher than Lipo-CBDCA intraperitoneal administration than with free CBDCA intraperitonead or intravenous administration. The amtitumor effects of Lipo-cBDCA were determined in rats with carcinomatous peritonitis due to AH130 tumors. Intraperitonead Lipo-CBDCA prolonged the life span of the rumor bearing rats. No side effects of the chemotherapy were observed in biochemical and histological studies in the liver, kidney, spleen, and small intestine. Frthermore, the effects of intraportal vein administration was examined using rats bearing AH130 tumors. The platinum cancentration in the liver following the intraportal vein administration was significantly higher with Lipo-CBDCA than with free-CBDCA.Lipo-CBDCA prolonged thelife span of the rats with liver metastases, compared with those of the control group and free-CBDCA group. These results indicate that intraperitoneal and intraportal vein chemotherapy with Lipo-CBCDA managing in carcinomatous peritonitis and hepatic metastases, and may be therapeutically useful without toxic side effects.
|
